GSK's Endometrial Cancer Treatment Study Shows Combination Potential
By Anthony O. Goriainoff
GSK said results from a study showed the potential for combinations of its Jemperli cancer treatment in patients with primary advanced or recurrent endometrial cancer.
Endometrial cancer is found in the inner lining of the uterus.
The U.K. pharmaceutical giant said Saturday that positive data from the phase 3 study showed Jemperli(dostarlimab)-based regimens could benefit a larger set of patients with endometrial cancer.
The company said dostarlimab plus chemotherapy was the only immuno-oncology combination to show statistically significant and clinically meaningful overall survival rate in the overall population. It added that it saw a 31% reduction in risk of death and a 16.4-month improvement in the median overall survival rate with dostarlimab plus chemotherapy versus chemotherapy alone, and a 37% reduction in risk of disease progression or death.
"Our goal is to continue to identify ways to use dostarlimab alone and in combination with other therapies to help improve outcomes for patients with limited treatment options," the company said.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
March 18, 2024 03:34 ET (07:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths